314 CHAPTER 4.1 Table SI1.2. Frequency and acceptance of CDSS-generated START signals in total and per country START criteria (n=31) All countries Belgium (BE) Switzerland (CH) Ireland (IE) The Netherlands (NL) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) TOTAL 1615 37.2% 236 43.2% 761 30.5% 192 55.7% 426 36.9% H 1. High-potency opioids in moderate-severe pain, where paracetamol, NSAIDs or lowpotency opioids are not appropriate to the pain severity or have been ineffective. 162 2.5% 25 4.0% 88 0% 28 0% 21 14.3% A 6. Angiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure and/or documented coronary artery disease. 133 51.1% 11 54.5% 48 64.6% 18 61.1% 56 35.7% E 4. Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate, strontium ranelate, teriparatide, denosumab) in patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores -> 2.5 in multiple sites) and/or previous history of fragility fracture(s). 118 43.2% 20 55.0% 59 32.2% 11 81.8% 28 42.9% H 2. Laxatives in patients receiving opioids regularly. 115 47.8% 41 51.2% 39 38.5% 10 90.0% 25 40.0% E 3. Vitamin D and calcium supplement in patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores more than -2.5 in multiple sites). 110 60.9% 22 59.1% 49 42.9% 14 78.6% 25 88.0%
RkJQdWJsaXNoZXIy MTk4NDMw